Re: Farmas USA
8k AMRN
http://www.sec.gov/Archives/edgar/data/897448/000119312513287377/d566392d8k.htm
24,955,000 American Depositary Shares (“ADSs”), including 3,255,000 ADSs issuable to the Underwriters pursuant to a 30-day option, with each ADS representing one of the Company’s ordinary shares, par value £0.50 per share.
The Underwriters purchased the ADSs from the Company at a price of $5.60 per ADS.
The net proceeds to us from the Offering are expected to be approximately $121.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses, assuming no exercise of the option by the Underwriters.
The Offering is expected to close on or about July 12, 2013, subject to customary closing conditions.
The Company currently intends to use the net proceeds from the Offering to continue the commercial launch of Vascepa® (icosapent ethyl) capsules in the MARINE indication, prepare for and commercially launch Vascepa in the ANCHOR indication, if approved, advance the Company’s REDUCE-IT cardiovascular outcomes trial, and for general corporate and working capital purposes.